Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Medical Condition: Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]"
topic_facet:"Phase: Phase 2"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
PubPharm (56)
1
An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma : A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma : A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
A clinical study to evaluate the safety, effectiveness and pharmacokinetics of Daratumumab given through the subcutaneous route in combination with standard bone marrow cancer treatment regimens : A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
A clinical study to evaluate the safety, effectiveness and pharmacokinetics of Daratumumab given through the subcutaneous route in combination with standard bone marrow cancer treatment regimens : A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab : Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab : Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
Treatment of unfit and frail newly diagnosed multiple myeloma patients with ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in .How effective is this treatment and how well is it tolerated? : Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma : A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
4
5
6
Nächster »
[6]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Medical Condition: Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Filter aufheben
Thema: Phase: Phase 2
Medienart
56
Aufsätze
56
E-Artikel
56
E-Ressourcen
Zeitschriftentitel
56
WHO International Clinical Trials Registry Plat...
Thema
56
610
Medical Condition: Multiple Myeloma MedDRA vers...
Phase: Phase 2
56
Recruitment Status: Authorised-recruitment may ...
56
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2
2023
12
2022
22
2021
20
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
56
Englisch
Haven't found what you're looking for?
Wird geladen...